Phase II study of regorafenib with dose adjustment and pharmacokinetic analysis in advanced colorectal cancer
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Interventions: Start with regorafenib 120mg/day, and escalate the dosage to 160mg/day if compatible with the criteria at day 15 Primary outcome(s): Desease control rate Study Design: Single arm Non-randomized
创建时间：
2016-08-15
